secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001140361-25-040774
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026
--------------------------------------------------------------------------------

- Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.
- Cash, equivalents, investments $222.8M; runway expected into Q2 2027.
- FDA accepted KRESLADI (marne-cel) BLA resubmission for severe LAD-I; PDUFA target March 28, 2026.
- Phase 2 trial of RP-A501 for Danon disease to resume dosing in 1H 2026 after FDA lifted clinical hold.
- Appointed Dr. Syed Rizvi as CMO, Christopher Stevens as COO, Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/0001140361-25-040774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125040774/ef20058531_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-040774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer